Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PREP | P48147 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049200 | 0.97 | SIGMAR1 (0.60) | SIGMAR1MEN1KMT2APREPHTT | |
| SCHEMBL18751212 | 0.97 | SIGMAR1 (0.60) | SIGMAR1MEN1KMT2APREPHTT | |
| SCHEMBL3048960 | 0.93 | SIGMAR1 (0.56) | SIGMAR1MEN1KMT2APREPL3MBTL1 | |
| SCHEMBL14691386 | 0.88 | SIGMAR1 (0.66) | SIGMAR1MEN1KMT2AL3MBTL1HTT | |
| SCHEMBL8750837 | 0.87 | PREP (0.60) | SIGMAR1KMT2APREPL3MBTL1HTT | |
| SCHEMBL16847349 | 0.85 | MEN1 (0.57) | MEN1KMT2AHTTGPR119 | |
| SCHEMBL8253758 | 0.85 | PREP (0.60) | MEN1KMT2APREPL3MBTL1HTT | |
| SCHEMBL11263011 | 0.85 | PREP (0.59) | SIGMAR1MEN1KMT2APREPL3MBTL1 | |
| SCHEMBL7159251 | 0.85 | PREP (0.59) | SIGMAR1MEN1KMT2APREPL3MBTL1 | |
| SCHEMBL2586953 | 0.84 | L3MBTL1 (0.61) | PREPL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605938-B1 | Antibacterial derivatives of napthydrin and quinoline | GLAXO GROUP LTD (GB) | 2009-02-11 | — | — | EP | disclosed |
| US-20060189601-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189601-A1 | Antibacterial agents | NQO2, NRDC, IFNG | SIGMAR1 1018/4885MEN1 3325/4885KMT2A 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.